Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-04-2010 | Review

Gastrin-releasing peptide links stressor to cancer progression

Authors: Xinqiu Li, Yunfu Lv, Aihua Yuan, Zongfang Li

Published in: Journal of Cancer Research and Clinical Oncology | Issue 4/2010

Abstract

Introduction

Gastrin-releasing peptide (GRP) plays an important role in cancer growth and metastasis; however, the mechanisms of how GRP affects cancer progression are not well understood. Recent studies revealed that chronic stress is a major risk factor for cancer progression, and this effect may be mediated by GRP. In this review, we will discuss the mechanisms and implications of GRP linking stressor to cancer progression.

Materials and methods

We retrieved the studies of the relationship between GRP, stress and cancers through PubMed using systematic methods to search, select, and evaluate the findings.

Results

The results suggested that GRP can mediate the effects of stress on cancers at systemic, tissue and cellular levels: Stress elicits the secretion of GRP in the brain and GRP in turn activates the stress response pathways resulting in an elevation of stress hormones and GRP in the plasma and tissues. GRP in synergy with stress hormones stimulates the growth and invasion of cancer cells by suppressing the anti-tumor immune function and directly activating the pro-proliferative and pro-migratory signaling pathways in cancer cells.

Conclusion

GRP is a multi-functional peptide, which acts as a stress mediator as well as a growth factor linking stressor to cancer progression. GRP and its high-affinity receptor are useful targets for the diagnosis and treatment of cancers.

Abujamra AL, Almeida VR, Brunetto AL, Schwartsmann G, Roesler R (2009) A gastrin-releasing peptide receptor antagonist stimulates neuro2a neuroblastoma cell growth: prevention by a histone deacetylase inhibitor. Cell Biol Int 33(8):899–903PubMedCrossRef

Algazi M, Plu-Bureau G, Flahault A et al (2006) Is beta-blocker treatment associated with a decrease in the risk of cancer. Lett Drug Des Discov 3(9):653–661CrossRef

Ananias HJ, van den Heuvel MC, Helfrich W, de Jong IJ (2009) Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate 69(10):1101–1108PubMedCrossRef

Anisman H (2009) Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. J Psychiatry Neurosci 34(1):4–20PubMed

Antoni MH, Lutgendorf SK, Cole SW et al (2006) The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer 6(3):240–248PubMedCrossRef

Armaiz-Pena GN, Lutgendorf SK, Cole SW, Sood AK (2009) Neuroendocrine modulation of cancer progression. Brain Behav Immun 23(1):10–15PubMedCrossRef

Axarli I, Labroua NE, Petroub C, Rassiasc N, Cordopatisb P, Clonis YD (2009) Sulphonamide-based bombesin prodrug analogues for glutathione transferase, useful in targeted cancer chemotherapy. Eur J Med Chem 44(5):2009–2016PubMedCrossRef

Bedard T, Mountney C, Kent P, Anisman H, Merali Z (2007) Role of gastrin-releasing peptide and neuromedin B in anxiety and fear-related behavior. Behav Brain Res 179(1):133–140PubMedCrossRef

Brown MR, Fisher LA (1984) Brain peptide regulation of adrenal epinephrine secretion. Am J Physiol Endocrinol Metab 247:41–46

Brown MR, Carver K, Fisher LA (1988) Bombesin: central nervous system actions to affect the autonomic nervous system. Ann N Y Acad Sci 547:174–182PubMedCrossRef

Cescato R, Maina T, Nock B et al (2008) Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 49(2):318–326PubMedCrossRef

Chao C, Ives K, Hellmich HL, Townsend CM Jr, Hellmich MR (2009) Gastrin-releasing peptide receptor in breast cancer mediates cellular migration and interleukin-8 expression. J Surg Res 156(1):26–31PubMedCrossRef

Chave HS, Gough AC, Palmer K, Preston SR, Primrose JN (2000) Bombesin family receptor and ligand gene expression in human colorectal cancer and normal mucosa. Br J Cancer 82(1):124–130PubMedCrossRef

Chen ST, Choo KB, Hou MF et al (2005) Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis 26:1241–1246PubMedCrossRef

Chinnappan D, Qu X, Xiao D et al (2008) Human gastrin-releasing peptide receptor gene regulation requires transcription factor binding at two distinct CRE sites. Am J Physiol Gastrointest Liver Physiol 295:153–162CrossRef

Clark MS, Bond MJ, Hecker JR (2007) Environmental stress, psychological stress and allostatic load. Psychol Health Med 12(1):18–30PubMedCrossRef

Cornelio DB, Roesler R, Schwartsmann G (2007) Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Ann Oncol 18:1457–1466PubMedCrossRef

Corral RS, Iniguez MA, Duque J, Lopez-Perez R, Fresno M (2007) Bombesin induces cyclooxygenase-2 expression through the activation of the nuclear factor of activated T cells and enhances cell migration in Caco-2 colon carcinoma cells. Oncogene 26:958–969PubMedCrossRef

Dantas Ados S, Luft T, Henriques JA, Schwartsmann G, Roesler R (2006) Opposite effects of low and high doses of the gastrin-releasing peptide receptor antagonist RC-3095 on memory consolidation in the hippocampus: possible involvement of the GABA ergic system. Peptides 27(9):2307–2312PubMedCrossRef

De la Fuente M, Del Rio M, Ferrandez MD, Hernanz A (1991) Modulation of phagocytic function in murine peritoneal macrophages by bombesin, gastrin-releasing peptide and neuromedin C. Immunology 73(2):205–211PubMed

De Oliveira MS, Cechim G, Braganhol E et al (2009) Anti-proliferative effect of the gastrin-release peptide receptor antagonist RC-3095 plus temozolomide in experimental glioblastoma models. J Neurooncol 93(2):191–201PubMedCrossRef

De Visser M, Bernard HF, Erion JL, Schmidt MA, Srinivasan A, Waser B, Reubi JC, Krenning EP, de Jong M (2007) Novel ¹¹¹In-labelled bombesin analogues for molecular imaging of prostate tumours. Eur J Nucl Med Mol Imaging 34:1228–1238PubMedCrossRef

Del Rio M, Hernanz A, De la Fuente M (1994) Bombesin, gastrin-releasing peptide, and neuromedin C modulate murine lymphocyte proliferation through adherent accessory cells and activate protein kinase C. Peptides 15(1):15–22PubMedCrossRef

Dumesny C, Patel O, Lachal S et al (2006) Synthesis, expression and biological activity of the prohormone for gastrin releasing peptide (ProGRP). Endocrinology 147:502–509PubMedCrossRef

Faintuch BL, Teodoro R, Duatti A, Muramoto E, Faintuch S, Smith CJ (2008) Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies. Nucl Med Biol 35:401–411PubMedCrossRef

Fang M, Liu C, Song Y et al (2004) Over-expression of gastrin-releasing peptide in human esophageal squamous cell carcinomas. Carcinogenesis 25(6):865–871PubMedCrossRef

Flores DG, Lenz G, Roesler R, Schwartsmann G (2009) Gastrin-releasing peptide receptor signaling in cancer. Cancer Ther 7:332–346

Fu L, Lee CC (2003) The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer 3(5):350–361PubMedCrossRef

Fujimura Y, Haruma K, Owen RL (2007) Bombesin prevents the atrophy of Peyer’s patches and the dysfunction of M cells in rabbits receiving song-term parenteral nutrition. J Parenter Enteral Nutr 31:75–85CrossRef

Gamble KL, Allen GC, Zhou T et al (2007) Gastrin-releasing peptide mediates light-like resetting of the suprachiasmatic nucleus circadian pacemaker through cAMP response element-binding protein and per1 activation. J Neurosci 27:12077–12087CrossRef

Garrido MM, Martin S, Ambrosio E et al (1998) Role of corticotropin-releasing hormone in gastrin-releasing peptide-mediated regulation of corticotropin and corticosterone secretion in male rats. Neuroendocrinology 68:116–122PubMedCrossRef

Garrido MM, Manzanares J, Fuentes JA (1999) Hypothalamus, anterior pituitary and adrenal gland involvement in the activation of adrenocorticotropin and corticosterone secretion by gastrin-releasing peptide. Brain Res 828:20–26PubMedCrossRef

Garrido MM, Fuentes JA, Manzanares J (2002) Gastrin-releasing peptide mediated regulation of 5-HT neuronal activity in the hypothalamic paraventricular nucleus under basal and restraint stress conditions. Life Sci 70(25):2953–2966PubMedCrossRef

Gonzalez N, Moody TW, Igarashi H, Ito T, Jensen RT (2008) Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states. Curr Opin Endocrinol Diabetes Obes 15(1):58–64PubMed

Goodspeed MC, Lee CC (2007) Tumor suppression and circadian function. J Biol Rhythms 22:291–298CrossRef

Hadcock JR, Wang HY, Malbon CC (1989) Agonist-induced destabilization of beta-adrenergic receptor mRNA. Attenuation of glucocorticoid-induced up-regulation of beta-adrenergic receptors. J Biol Chem 264:19928–19933PubMed

Hajri A, Balboni G, Koenig M et al (1992) Gastrin-releasing peptide: in vivo and in vitro growth effects on an acinar pancreatic carcinoma. Cancer Res 52:3726–3732PubMed

Hasegawa H, Saiki I (2002) Psychosocial stress augments tumor development through beta-adrenergic activation in mice. Jpn J Cancer Res 93(7):729–735PubMed

Hastings MH, Maywood ES, O’Neill JS (2008) Cellular circadian pacemaking and the role of cytosolic rhythms. Curr Biol 18(17):805–815CrossRef

Hellmich MR, Ives KL, Udupi V et al (1999) Multiple protein kinase pathways are involved in gastrin-releasing peptide receptor-regulated secretion. J Biol Chem 274:23901–23909PubMedCrossRef

Herschbach P, Book K, Brandl T, Keller M, Lindena G, Neuwohner K, Mittag BM (2008) Psychological distress in cancer patients assessed with an expert rating scale. Br J Cancer 99:37–43PubMedCrossRef

Hohla F, Schally AV, Kanashiro CA et al (2007) Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-Ras, COX-2, and pAkt. PNAS 104:18671–18676PubMedCrossRef

Ischia J, Patel O, Shulkes A, Baldwin GS (2009) Gastrin-releasing peptide: different forms, different functions. Int Union Biochem Mol Biol 35(1):69–75

Karatsoreos IN, Romeo RD, McEwen BS et al (2006) Diurnal regulation of the gastrin-releasing peptide receptor in the mouse circadian clock. Eur J Neurosci 23(4):1047–1053PubMedCrossRef

Kelley MJ, Linnoila RI, Avis IL et al (1997) Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest 112:256–261PubMedCrossRef

Kent P, Anisman H, Merali Z (1998) Are bombesin-like peptides involved in the mediation of stress response? Life Sci 62(2):103–114PubMedCrossRef

Lango MN, Dyer KF, Lui VW, Gooding WE, Gubish C, Siegfried JM, Grandis JR (2002) Gastrin-releasing peptide receptor-mediated autocrine growth in squamous cell carcinoma of the head and neck. J Natl Cancer Inst 94:375–383PubMed

Layton JE, Scanlon DB, Soveny C et al (1988) Effects of bombesin antagonists on the growth of small cell lung cancer cells in vitro. Cancer Res 48:4783–4789PubMed

Lehy T, Accary JP, Labeille D et al (1983) Chronic administration of bombesin stimulates antral gastrin cell proliferation in the rat. Gastroenterology 84:914–919PubMed

Lemaire I (1991) Bombesin-related peptides modulate interleukin-1 production by alveolar macrophages. Neuropeptides 20(4):217–223PubMedCrossRef

Lenz HJ (1988) CNS regulation of gastric and autonomic functions in dogs by gastrin-releasing peptide. Am J Physiol 255:298–303

Liu X, Carlisle DL, Swick MC et al (2007) Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib. Exp Cell Res 313:1361–1372PubMedCrossRef

Lloyd-Williams M, Shiels C, Taylor F, Dennis M (2009) Depression—an independent predictor of early death in patients with advanced cancer. J Affect Disord 113:127–132PubMedCrossRef

Lutgendorf SK, Cole S, Costanzo E et al (2003) Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res 9:4514–4521PubMed

Makarenkova VP, Shurin GV, Tourkova IL et al (2003) Lung cancer-derived bombesin-like peptides down-regulate the generation and function of human dendritic cells. J Neuroimmunol 145:55–67PubMedCrossRef

Mantovani A, Sozzani S, Locati M et al (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23(11):549–555PubMedCrossRef

Marinissen MJ, Gutkind JS (2001) G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci 22:368–376PubMedCrossRef

Markwalder R, Reubi JC (1999) Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 59:1152–1159PubMed

McArthur AJ, Coogan AN, Ajpru S et al (2000) Gastrin-releasing peptide phase-shifts suprachiasmatic nuclei neuronal rhythms in vitro. J Neurosci 20:5496–5502PubMed

Merali Z, Kent P, Anisman H (2002) Role of bombesin-related peptides in the mediation or integration of the stress response. Cell Mol Life Sci 59(2):272–287PubMedCrossRef

Merali Z, Hayley S, Kent P, McIntosh J, Bedard T, Anisman H (2009) Impact of repeated stressor exposure on the release of corticotropin-releasing hormone, arginine-vasopressin and bombesin-like peptides at the anterior pituitary. Behav Brain Res 198:105–112PubMedCrossRef

Mikosz CA, Brickley DR, Sharkey MS et al (2001) Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. J Biol Chem 276:16649–16654PubMedCrossRef

Minamino N, Kangawa K, Matsuo H et al (1983) A novel bombesin-like peptide identified in porcine spinal cord. Biochem Biophys Res Commun 114:541–548PubMedCrossRef

Miovic M, Block S (2007) Psychiatric disorders in advanced cancer. Cancer 110(8):1665–1676PubMedCrossRef

Molina R, Filella X, Auge JM (2009) ProGRP: a new biomarker for small cell lung cancer. Clin Biochem 37:505–511CrossRef

Moody TW, Merali Z (2004) Bombesin-like peptides and associated receptors within the brain: distribution and behavioral implications. Peptides 25(3):511–520PubMedCrossRef

Moustafa AE, Tsao Md, Battey JF et al (1995) Expression of the gastrin-releasing peptide receptor confers a growth response to bombesin in immortalized human bronchial epithelial cells. Cancer Res 55:1853–1855PubMed

Nagakawa O, Furuya Y, Fujiuchi Y, Fuse H (2002) Serum pro-gastrin-releasing peptide (31–98) in benign prostatic hyperplasia and prostatic carcinoma. Urology 60:527–530PubMedCrossRef

Norgaard P, Poulsen HS (1991) Glucocorticoid receptors in human malignancies: a review. Ann Oncol 2:541–557PubMed

Novak J, Schleman S, Scott J et al (2004) Dexamethasone regulation of gastrin-releasing peptide receptor in human lung cells. Lung Cancer 43(1):17–28PubMedCrossRef

Okarvi SM (2008) Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer. Cancer Treat Rev 34:13–26PubMedCrossRef

Okarvi SM, Jammaz IA (2009) Design, synthesis, radiolabeling and in vitro and in vivo characterization of tumor-antigen- and antibody-derived peptides for the detection of breast cancer. Anticancer Res 29(4):1399–1409PubMed

Okubo M, Kaku K, Kaneko T et al (1985) Effects of bombesin and gastrin releasing peptide on catecholamine secretion from rat adrenal gland, in vitro. Endocrinol Jpn 32(1):21–27PubMed

Panula P (1986) Histochemistry and function of bombesin-like peptides. Med Biol 64(4):177–192PubMed

Patel O, Shulkes A, Baldwin GS (2006) Gastrin-releasing peptide and cancer. BBA Rev Cancer 1766(1):23–41

Petrella A, Ercolino SF, Festa M et al (2006) Dexamethasone inhibits TRAIL-induced apoptosis of thyroid cancer cells via Bcl-xL induction. Eur J Cancer 42(18):3287–3293PubMedCrossRef

Qiao J, Kang J, Cree J, Mark Evers B, Chung DH (2005) Gastrin-releasing peptide-induced down-regulation of tumor suppressor protein PTEN (phosphatase and tensin homolog deleted on chromosome ten) in neuroblastomas. Ann Surg 241:684–685PubMedCrossRef

Qiao J, Kang J, Ishola TA, Rychahou PG, Evers BM, Chung DH (2008) Gastrin-releasing peptide receptor silencing suppresses the tumorigenesis and metastatic potential of neuroblastoma. PNAS 105(35):12891–12896PubMedCrossRef

Qin Y, Ertl T, Cai RZ, Halmos G, Sehally AV (1994a) Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro. Cancer Res 54:1035–11141PubMed

Qin Y, Halmos G, Cai RZ, Szoke B, Ertl T, Schally AV (1994b) Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors. J Cancer Res Clin Oncol 120:519–528PubMedCrossRef

Qu X, Xiao D, Weber HC (2002) Human gastrin-releasing peptide receptor mediates sustained CREB phosphorylation and transactivation in HuTu 80 duodenal cancer cells. FEBS Lett 527:109–113PubMedCrossRef

Reiche EM, Nunes SO, Morimoto HK (2004) Stress, depression, the immune system, and cancer. Lancet Oncol 5(10):617–625PubMedCrossRef

Rivera CA, Ahlberg NC, Taglia L, Kumar M, Blunier A, Benya RV (2009) Expression of GRP and its receptor is associated with improved survival in patients with colon cancer. Clin Exp Metastasis 26(7):663–671PubMedCrossRef

Roesler R, Henriques JA, Schwartsmann G (2006) Gastrin-releasing peptide receptor as a molecular target for psychiatric and neurological disorders. CNS Neurol Disord Drug Targets 5(2):197–204PubMedCrossRef

Rozengurt E, Sinnett-Smith J (1983) Bombesin stimulation of DNA synthesis and cell division in cultures of swiss 3T3 cells. PNAS 80:2936–2940PubMedCrossRef

Runnebaum IB, Bruning A (2005) Glucocorticoids Inhibit Cell death in ovarian cancer and up-regulate caspase inhibitor cIAP2. Clin Cancer Res 11:6325–6332PubMedCrossRef

Sahar S, Corsi PS (2009) Metabolism and cancer: the circadian clock connection. Nat Rev Cancer 9:886–896PubMedCrossRef

Saurin JC, Fallavier M, Sordat B et al (2002) Bombesin stimulates invasion and migration of isreco1 colon carcinoma cells in a Rho-dependent manner. Cancer Res 62:4829–4835PubMed

Schuhmacher J, Zhang H, Doll J et al (2005) GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a ⁶⁸Ga-labeled bombesin (6–14) analog. J Nucl Med 46(4):691–699PubMed

Serafeim A, Holder MJ, Grafton G et al (2003) Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood 101:3212–3219PubMedCrossRef

Shimizu T, Okada S, Yamaguchi N et al (2005) Brain phospholipase C/diacylglycerol lipase are involved in bombesin BB2 receptor-mediated activation of sympatho-adrenomedullary outflow in rats. Eur J Pharmacol 514(2–3):151–158PubMed

Sinnett Smith J, Zhukova E, Hsieh N et al (2004) Protein kinase D potentiates DNA synthesis induced by Gq-coupled receptors by increasing the duration of ERK signaling in swiss 3T3 Cells. J Biol Chem 279:16883–16893PubMedCrossRef

Sood AK, Bhatty R, Kamat AA et al (2006) Stress hormone–mediated invasion of ovarian cancer cells. Clin Cancer Res 12:369–375PubMedCrossRef

Spindel ER, Chin WW, Price J, Rees LH, Besser GM, Habener JF (1984) Cloning and characterization of cDNAs encoding human gastrin-releasing peptide. Proc Natl Acad Sci USA 81:5699–5703PubMedCrossRef

Sterniczuk R, Colijn MA, Nunez M, Antle MC (2010) Investigating the role of substance P in photic responses of the circadian system: individual and combined actions with gastrin-releasing peptide. Neuropharmacology 58(1):277–285PubMedCrossRef

Thaker PH, Han LY, Kamat AA et al (2006) Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 12(8):939–944PubMedCrossRef

Uchida K, Kojima A, Morokawa N, Tanabe O, Anzai C, Kawakami M, Eto Y, Yoshimura K (2002) Expression of progastrin-releasing peptide and gastrin-releasing peptide receptor mRNA transcripts in tumor cells of patients with small cell lung cancer. J Cancer Res Clin Oncol 128(12):633–640PubMedCrossRef

Vanitallie TB (2002) Stress:a risk factor for serious illness. Metabolism 51:40–45PubMedCrossRef

Wael AE, Fabio G, Jered G et al (2008) Design, synthesis and biological evaluation of a radiolabelled antagonist-bombesin analog as targeting vector. Bioconjug Chem 19(10):2040–2048CrossRef

Willey JC, Lechner JF, Harris CC (1984) Bombesin and the C-terminal tetradecapeptide of gastrin-releasing peptide are growth factors for normal human bronchial epithelial cells. Exp Cell Res 153(1):245–283PubMedCrossRef

Wu W, Zou M, Brickley DR et al (2006) Glucocorticoid receptor activation signals through forkhead transcription factor 3a in breast cancer cells. Mol Endocrinol 20:2304–2314PubMedCrossRef

Wu G, Guo W, Ouyan K et al (2008) A novel vaccine targeting gastrin-releasing peptide: efficient inhibition of breast cancer growth in vivo. Endocr Relat Cancer 15:149–159CrossRef

Xiao D, Wang J, Lori L et al (2001) The human gastrin-releasing peptide receptor gene structure, its tissue expression and promoter. Gene 264(1):95–100PubMedCrossRef

Xiao D, Qu X, Weber HC (2003) Activation of extracellular signal-regulated kinase mediates bombesin-induced mitogenic responses in prostate cancer cells. Cell Signal 15(10):945–953PubMedCrossRef

Yang EV, Sood AK, Min C et al (2006) Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 66:10357–10364PubMedCrossRef

Zhang L, Cui R, Cheng X et al (2005) Antiapoptotic effect of serum and glucocorticoid-inducible protein kinase is mediated by novel mechanism activating IκB kinase. Cancer Res 65:457–464PubMed

Zhang Q, Thomas SM, Lui VW, Xi S, Siegfried JM, Fan H, Smithgall TE, Mills GB, Grandis JR (2006) Phosphorylation of TNF-α converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. PNAS 103:6901–6906PubMedCrossRef

Title: Gastrin-releasing peptide links stressor to cancer progression
Authors: Xinqiu Li
Yunfu Lv
Aihua Yuan
Zongfang Li
Publication date: 01-04-2010
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 4/2010
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-010-0766-2

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2010

Genomic aberrations in hepatocellular carcinoma related to osteopontin expression detected by array-CGH

The similar survival benefits of stable disease and partial response to pemetrexed in previously treated non-small cell carcinoma patients

Erratum to: Overexpression of Cks1 is associated with poor survival by inhibiting apoptosis in breast cancer

Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer

US-guided interstitial chemotherapy using paclitaxel temperature-responsive gel for breast cancer treatment in rat

Age as a prognostic factor for patients with osteosarcoma: an analysis of 438 patients

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage